BRAF and cancer: The use of next-generation sequencing to identify gene alterations, including BRAF mutations, RET, ALK and NTRK gene fusions, depends on the availability of such testing and NHS England is currently establishing a national test directory service over seven genomic hubs UK-wide to carry out cancer genomic testing by next-generation sequencing and interpret all results.